Title:
6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/140959
Kind Code:
A1
Abstract:
A 6-oxo-1,6-dihydropyridazine derivative, a preparation method therefor and medical use thereof, in particular, a 6-oxo-1,6-dihydropyridazine derivative represented by general formula (I), a preparation method therefor, and a pharmaceutical composition containing the derivative, and use thereof as a NaV inhibitor and use thereof in the preparation of a drug for the treatment and/or prevention of pain and pain-related diseases. Each substituent in general formula (I) is the same as defined in the description.
More Like This:
| JPS5555167 | SUBSTITUTED PYRIDAZONES AND HERBICIDE CONTAINING THEM |
| JP2021535169 | Carboxamide and sulfonamide derivatives useful as TEAD modulators |
| WO/1996/039392 | PHENYLPYRIDAZINONES |
Inventors:
YANG FANGLONG (CN)
YU NAN (CN)
CHI JIANGTAO (CN)
HE FENG (CN)
TAO WEIKANG (CN)
YU NAN (CN)
CHI JIANGTAO (CN)
HE FENG (CN)
TAO WEIKANG (CN)
Application Number:
PCT/CN2020/070186
Publication Date:
July 09, 2020
Filing Date:
January 03, 2020
Export Citation:
Assignee:
JIANGSU HENGRUI MEDICINE CO (CN)
SHANGHAI HENGRUI PHARMACEUTICAL CO LTD (CN)
SHANGHAI HENGRUI PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D237/22; A61K31/166; A61K31/50; A61P25/00; A61P29/00; C07C235/64
Domestic Patent References:
| WO2018213426A1 | 2018-11-22 | |||
| WO2018213426A1 | 2018-11-22 |
Foreign References:
| CN105026373A | 2015-11-04 | |||
| CN105026373A | 2015-11-04 | |||
| CN104968647A | 2015-10-07 | |||
| CN101883758A | 2010-11-10 |
Other References:
RUSH A.M. ET AL., J. PHYSIOL., vol. 579, 2007, pages 1 - 14
GOLDIN A.L. ET AL., ANNU. REV. PHYSIOL., vol. 63, 2001, pages 871 - 894
FOZZARD H.A. ET AL., PHYSIOL. REV., vol. 76, 1996, pages 887 - 926
DIB-HAJJ S.D. ET AL., ANNU. REV. NEUROSCI., vol. 33, 2010, pages 325 - 347
SLEEPER A.A. ET AL., J.NEUROSCI., vol. 20, 2000, pages 7279 - 7289
YOSHIMURA N. ET AL., J.NEUROSCI., vol. 21, 2001, pages 8690 - 8696
TANAKA M. ET AL., G. NEUROREPORT, vol. 9, 1998, pages 967 - 972
KERR B.J. ET AL., NEUROREPORT, vol. 12, 2001, pages 3077 - 3080
FABER C.G. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 109, 2012, pages 19444 - 19449
See also references of EP 3907218A4
GOLDIN A.L. ET AL., ANNU. REV. PHYSIOL., vol. 63, 2001, pages 871 - 894
FOZZARD H.A. ET AL., PHYSIOL. REV., vol. 76, 1996, pages 887 - 926
DIB-HAJJ S.D. ET AL., ANNU. REV. NEUROSCI., vol. 33, 2010, pages 325 - 347
SLEEPER A.A. ET AL., J.NEUROSCI., vol. 20, 2000, pages 7279 - 7289
YOSHIMURA N. ET AL., J.NEUROSCI., vol. 21, 2001, pages 8690 - 8696
TANAKA M. ET AL., G. NEUROREPORT, vol. 9, 1998, pages 967 - 972
KERR B.J. ET AL., NEUROREPORT, vol. 12, 2001, pages 3077 - 3080
FABER C.G. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 109, 2012, pages 19444 - 19449
See also references of EP 3907218A4
Attorney, Agent or Firm:
GE CHENG & CO., LTD. (CN)
Download PDF: